Abseil Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.83 M
- Revenue Growth 42.98%
- Profit Growth -4.42%
- Ebitda 7.35%
- Net Worth 34.06%
- Total Assets 62.85%
About Abseil Pharmaceuticals
Abseil Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 January 2014 and has a history of 11 years and one month. Its registered office is in Burdwan, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.83 M.
Madan Pandit, Tanmoy Pathak, and Nabarun Das serve as directors at the Company.
Company Details
- Location
Burdwan, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233WB2014PTC199680
- Company No.
199680
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jan 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Abseil Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madan Pandit  | Director | 21-Jan-2014 | Current |
| Tanmoy Pathak | Director | 21-Jan-2014 | Current |
| Nabarun Das | Director | 15-Jan-2015 | Current |
Financial Performance of Abseil Pharmaceuticals.
Abseil Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 42.98% increase. The company also saw a slight decrease in profitability, with a 4.42% decrease in profit. The company's net worth Soared by an impressive increase of 34.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abseil Pharmaceuticals?
In 2023, Abseil Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.83 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.18 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jun 2020 | Others | ₹1.83 M | Open |
How Many Employees Work at Abseil Pharmaceuticals?
Abseil Pharmaceuticals has a workforce of 25 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abseil Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abseil Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.